Leukemia News

Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation (November 29, 2018)

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata has demonstrated inhibitory activity against... Continue Reading

FDA Approves Venclexta Combination for AML in Adults (November 26, 2018)

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years... Continue Reading

duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (September 25, 2018)

The Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In... Continue Reading

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation (July 23, 2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation... Continue Reading

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion, (June 25, 2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval... Continue Reading

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia (March 22, 2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has... Continue Reading

CRISPR Enhances Cancer Immunotherapy (March 14, 2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells —... Continue Reading

U.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute Promyelocytic Leukemia (January 31, 2018)

CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL)... Continue Reading

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (January 14, 2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous... Continue Reading

Pass it On: It’s Leukemia National Awareness Month (September 19, 2017)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia and 24,400 deaths in 2016. For lymphoma, the ACS estimates... Continue Reading

Latest Leukemia News By Stage


Acute Lymphoblastic Leukemia

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia (August 22, 2017)

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children... Continue Reading

More Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation (November 29, 2018)

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata has demonstrated inhibitory activity against... Continue Reading

FDA Approves Venclexta Combination for AML in Adults (November 26, 2018)

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years... Continue Reading

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation (July 23, 2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation... Continue Reading

U.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute Promyelocytic Leukemia (January 31, 2018)

CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL)... Continue Reading

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for... Continue Reading

More Acute Myeloid Leukemia

Acute Promyelocytic Leukemia

Sorry, there are no articles available for this cancer stage.

More Acute Promyelocytic Leukemia

Adult Acute Lymphoblastic Leukemia

Sorry, there are no articles available for this cancer stage.

More Adult Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia

Sorry, there are no articles available for this cancer stage.

More Childhood Acute Lymphoblastic Leukemia

Chronic Lymphoblastic Leukemia

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients (June 5, 2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman... Continue Reading

More Chronic Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (September 25, 2018)

The Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In... Continue Reading

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion, (June 25, 2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval... Continue Reading

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia (March 22, 2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has... Continue Reading

Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (September 11, 2017)

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced... Continue Reading

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients (June 5, 2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman... Continue Reading

More Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (January 14, 2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous... Continue Reading

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia (June 14, 2017)

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended the lives of patients... Continue Reading

More Chronic Myeloid Leukemia

Hairy Cell Leukemia

Sorry, there are no articles available for this cancer stage.

More Hairy Cell Leukemia

Screening/Prevention Leukemia

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Leukemia